Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The festive season is here, so you know what that means: it's party time! We've got just what you need to start up the conversation and get everyone in the mood. Whether you're playing Never Have I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback